These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with Al-Saden N; Lam K; Chan C; Reilly RM Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952 [TBL] [Abstract][Full Text] [Related]
4. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305 [TBL] [Abstract][Full Text] [Related]
5. Tumor uptake and tumor/blood ratios for [ Al-Saden N; Cai Z; Reilly RM Nucl Med Biol; 2018 Dec; 67():43-51. PubMed ID: 30390575 [TBL] [Abstract][Full Text] [Related]
6. Tracking of NK Cells by Positron Emission Tomography Using Sato N; Szajek LP; Choyke PL Methods Mol Biol; 2022; 2463():153-161. PubMed ID: 35344173 [TBL] [Abstract][Full Text] [Related]
7. HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer. Pereira PMR; Ragupathi A; Shmuel S; Mandleywala K; Viola NT; Lewis JS Mol Pharm; 2020 Jan; 17(1):327-337. PubMed ID: 31804840 [TBL] [Abstract][Full Text] [Related]
8. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with McKnight BN; Viola-Villegas NT Breast Cancer Res; 2018 Oct; 20(1):130. PubMed ID: 30359299 [TBL] [Abstract][Full Text] [Related]
9. Tribody [(HER2) Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D Front Immunol; 2018; 9():814. PubMed ID: 29725336 [TBL] [Abstract][Full Text] [Related]
11. Imaging of HER2 with [ Massicano AVF; Lee S; Crenshaw BK; Aweda TA; El Sayed R; Super I; Bose R; Marquez-Nostra BV; Lapi SE Cancer Biother Radiopharm; 2019 May; 34(4):209-217. PubMed ID: 30676778 [No Abstract] [Full Text] [Related]
12. Paclitaxel enhances antibody-dependent cell-mediated cytotoxicity of trastuzumab by rapid recruitment of natural killer cells in HER2-positive breast cancer. Miura D; Yoneyama K; Furuhata Y; Shimizu K J Nippon Med Sch; 2014; 81(4):211-20. PubMed ID: 25186575 [TBL] [Abstract][Full Text] [Related]
13. Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer. Collins DM; Madden SF; Gaynor N; AlSultan D; Le Gal M; Eustace AJ; Gately KA; Hughes C; Davies AM; Mahgoub T; Ballot J; Toomey S; O'Connor DP; Gallagher WM; Holmes FA; Espina V; Liotta L; Hennessy BT; O'Byrne KJ; Hasmann M; Bossenmaier B; O'Donovan N; Crown J Clin Cancer Res; 2021 Feb; 27(3):807-818. PubMed ID: 33122343 [TBL] [Abstract][Full Text] [Related]
14. (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. Oude Munnink TH; Korte MA; Nagengast WB; Timmer-Bosscha H; Schröder CP; Jong JR; Dongen GA; Jensen MR; Quadt C; Hooge MN; Vries EG Eur J Cancer; 2010 Feb; 46(3):678-84. PubMed ID: 20036116 [TBL] [Abstract][Full Text] [Related]
15. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Dijkers EC; Oude Munnink TH; Kosterink JG; Brouwers AH; Jager PL; de Jong JR; van Dongen GA; Schröder CP; Lub-de Hooge MN; de Vries EG Clin Pharmacol Ther; 2010 May; 87(5):586-92. PubMed ID: 20357763 [TBL] [Abstract][Full Text] [Related]
16. Dual-isotope imaging allows in vivo immunohistochemistry using radiolabelled antibodies in tumours. Knight JC; Mosley MJ; Kersemans V; Dias GM; Allen PD; Smart S; Cornelissen B Nucl Med Biol; 2019 Mar; 70():14-22. PubMed ID: 30825614 [TBL] [Abstract][Full Text] [Related]
17. Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression. Masu T; Atsukawa M; Nakatsuka K; Shimizu M; Miura D; Arai T; Harimoto H; Kondo C; Kaneko K; Futagami S; Kawamoto C; Takahashi H; Iwakiri K PLoS One; 2018; 13(12):e0200664. PubMed ID: 30596643 [TBL] [Abstract][Full Text] [Related]